List of Excipients in Branded Drug CARNITOR SF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Leadiant Biosciences Inc	CARNITOR SF	levocarnitine	54482-148	MALIC ACID
Leadiant Biosciences Inc	CARNITOR SF	levocarnitine	54482-148	METHYLPARABEN
Leadiant Biosciences Inc	CARNITOR SF	levocarnitine	54482-148	PROPYLPARABEN
Leadiant Biosciences Inc	CARNITOR SF	levocarnitine	54482-148	SACCHARIN SODIUM

CARNITOR SF Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

CARNITOR SF is a sugar-free oral levocarnitine solution used for primary and secondary carnitine deficiency. Its commercial differentiation depends more on taste, preservative performance, pediatric usability, supply reliability, and regulatory execution than on active-ingredient exclusivity. The core formulation uses a buffered, sweetened, flavored aqueous system with parabens as preservatives. Levocarnitine has long generic exposure, so commercial opportunities center on formulation improvement, regional registration, alternative presentations, and lifecycle management.

What is CARNITOR SF and how is it formulated?

CARNITOR SF is an oral solution containing levocarnitine, also known as L-carnitine. The U.S. Carnitor oral solution contains 1 gram of levocarnitine per 10 mL and is indicated for treatment of primary and secondary carnitine deficiency [1].

Public U.S. labeling identifies the following functional excipient categories:

Formulation element	Publicly identified role
Purified water	Aqueous vehicle
Citric acid and sodium citrate	Buffer system and pH control
Saccharin sodium	High-intensity sweetener
Natural and artificial flavors	Taste masking
Methylparaben and propylparaben	Antimicrobial preservation
Levocarnitine	Active pharmaceutical ingredient

The formulation is sugar-free. That characteristic is commercially relevant because patients with inherited metabolic disorders may require chronic administration, while some patients with renal disease, diabetes, or restricted carbohydrate intake may prefer a non-sucrose liquid.

The FDA label specifies an acidic formulation with a pH range of approximately 3.0 to 6.5 [1]. The low-pH environment supports preservation and may contribute to chemical stability, but it also creates taste and tolerability challenges.

What excipient strategy supports CARNITOR SF?

The current excipient strategy uses four technical controls: sugar-free sweetening, acid buffering, flavor masking, and preservative protection.

Sweetener selection

Saccharin sodium provides sweetness without adding sucrose or a meaningful carbohydrate load. The principal commercial advantage is compatibility with sugar-free positioning. Its limitations include a bitter or metallic aftertaste at higher concentrations and potential interaction with flavor systems.

Potential replacement or supplemental sweeteners include:

• Sucralose for a cleaner sweetness profile at low use levels.
• Acesulfame potassium for sweetness intensity and formulation flexibility.
• Steviol glycosides for a plant-derived positioning, subject to taste and regulatory review.
• Polyols such as sorbitol or maltitol where their gastrointestinal effects and carbohydrate labeling are acceptable.

A reformulation should avoid introducing a sweetener that creates a new patient burden. Sorbitol, for example, can cause gastrointestinal symptoms and may be unsuitable for certain pediatric or metabolic-disorder populations.

Buffer and pH control

Citric acid and sodium citrate provide pH control and can moderate flavor perception. The buffer system also affects preservative performance, active stability, container compatibility, and microbial control.

A commercial reformulation should establish:

• pH drift throughout shelf life.
• Levocarnitine assay and degradation profile.
• Preservative effectiveness after repeated opening.
• Compatibility with oral syringes and dosing cups.
• Stability in high-density polyethylene and polyethylene terephthalate packaging.
• Impact of pH on flavor release and aftertaste.

Any pH change must be treated as a product-quality change rather than a simple taste adjustment. It can affect preservative efficacy and the extractables-and-leachables profile of the container closure system.

Flavor masking

Levocarnitine can produce a strong, distinctive odor and taste. Flavor is likely the most important excipient-driven barrier to adherence. Fruity profiles, including citrus, berry, grape, and orange, are common commercial options, but the optimal choice depends on age group and dose volume.

A stronger flavor system may improve acceptability but can increase:

• Flavor instability during storage.
• Batch-to-batch sensory variability.
• Interaction with preservatives.
• Risk of allergen or labeling complications.
• Need for additional flavor qualification in different markets.

Taste-masking work should use a structured sensory program with pediatric-age segmentation. A flavor accepted by adults may perform poorly in young children, especially when the prescribed dose requires repeated daily administration.

Preservative system

Methylparaben and propylparaben provide established antimicrobial protection in aqueous oral products. Their advantages include long regulatory history, low cost, and broad availability. Their drawbacks include growing consumer sensitivity to parabens, possible precipitation or solubility concerns, and the need to demonstrate effective concentration across the product’s pH range.

Alternative systems could include potassium sorbate, sodium benzoate, or combination systems. Each alternative requires evaluation of:

• Preservative effectiveness testing.
• pH dependence.
• Interaction with flavors and sweeteners.
• Pediatric exposure.
• Regional excipient acceptability.
• Container closure compatibility.
• Microbial risk after opening.

A preservative-free version may be attractive for certain markets, but it would require a fundamentally different multidose strategy. Unit-dose packaging, aseptic filling, or a validated in-use period could replace chemical preservation. Those options would raise packaging and manufacturing costs.

What formulations are protected by CARNITOR SF patents?

No active-ingredient patent barrier is apparent for levocarnitine. The product’s commercial position is therefore primarily formulation- and brand-based rather than dependent on a current composition-of-matter patent.

Patent or exclusivity category	CARNITOR SF assessment
Levocarnitine composition patent	Not commercially controlling for current market access
Sugar-free oral-solution patent	No controlling public patent identified in the cited product labeling
Method-of-use patent	No product-specific patent identified in the cited label
Pediatric formulation patent	No controlling patent identified
Orange Book-listed patent	Must be verified against the current FDA Orange Book entry
Regulatory exclusivity	No current new-drug exclusivity is apparent from the long commercial history
Biosimilar exclusivity	Not applicable; levocarnitine is a small molecule

FDA product labeling identifies the active ingredient and excipient system but does not itself establish a patent term or enforceable formulation monopoly [1]. Any current patent analysis should distinguish CARNITOR SF from later levocarnitine products, combination products, delivery technologies, and jurisdiction-specific patents.

When does CARNITOR SF lose exclusivity?

CARNITOR SF is already exposed to generic competition because levocarnitine is an established small-molecule active ingredient with long regulatory history. The relevant commercial question is not the end of a near-term patent term. It is whether a competitor can obtain approval for an equivalent oral solution or launch a differentiated liquid product.

Generic entry can occur through an abbreviated pathway where the applicant demonstrates pharmaceutical equivalence, quality, and bioequivalence or another appropriate regulatory basis. For an oral solution, the regulatory burden may differ from that of a tablet because the solution does not require dissolution testing in the same way. The applicant still must address active concentration, excipients, microbial quality, stability, preservative performance, and labeling.

What Paragraph IV challenges affect CARNITOR SF?

A Paragraph IV certification is relevant only where a listed patent appears in the FDA Orange Book and an ANDA applicant seeks approval before patent expiry. No specific Paragraph IV litigation can be confirmed from the cited public product information.

The most likely competitive pathway for a levocarnitine oral solution is an ANDA relying on the reference product, provided the reference product and listed patents satisfy FDA requirements. The practical barriers are formulation similarity, taste, manufacturing scale, preservative control, and market access rather than a complex patent estate.

What is the FDA regulatory status of CARNITOR SF?

CARNITOR is an FDA-approved prescription product for primary and secondary carnitine deficiency. The U.S. label identifies oral solution and tablet presentations and lists Leadiant Biosciences, Inc. as the marketing company in the current labeling source [1].

The principal regulatory controls are:

1. Correct levocarnitine concentration.
2. Demonstrated chemical and microbiological stability.
3. Validated preservative effectiveness.
4. Accurate dosing-device performance.
5. Control of impurities and degradation products.
6. Appropriate labeling for chronic use and patient populations.
7. Compliance with current good manufacturing practices.

The FDA Inactive Ingredient Database can support assessment of precedent for proposed substitute excipients, but database presence does not eliminate the need for product-specific safety and quality justification [2].

What commercial opportunities exist for CARNITOR SF?

The strongest opportunities involve patient adherence and differentiated delivery rather than a new therapeutic indication.

Pediatric and metabolic-disorder positioning

Primary carnitine deficiency and related metabolic disorders often require long-term treatment. A more acceptable flavor, lower dosing volume, or easier dispensing system could improve adherence.

Potential product concepts include:

• Concentrated oral solution requiring lower daily volume.
• Unit-dose cups or stick packs.
• Oral-syringe-compatible packaging.
• Improved child-oriented flavor systems.
• Tamper-evident multidose bottles.
• A preservative-reduced or preservative-free unit-dose product.

A concentrated product would need careful assessment of local tolerability, dosing accuracy, osmolality, and accidental overdose risk.

Sugar-free and dietary positioning

The sugar-free attribute can support continued use in patients who avoid sucrose. It also provides a point of differentiation against liquid products containing sucrose or high levels of polyols. Marketing claims must remain consistent with the approved labeling and local advertising rules.

Supply-chain and manufacturing opportunity

The formulation relies on widely available excipients. That reduces technical supply risk but also limits formulation exclusivity. Commercial advantage may come from:

• Dual sourcing of parabens, sweeteners, and flavors.
• Regional flavor variants using the same active formulation.
• Flexible fill-finish capacity.
• Improved bottle and dosing-device components.
• Contract manufacturing for private-label or regional products.

Flavor systems and child-resistant packaging may create more operational complexity than the active ingredient itself.

How does CARNITOR SF compare with alternative levocarnitine products?

Attribute	CARNITOR SF	Generic levocarnitine oral solution	Levocarnitine tablets or capsules
Dosage form	Sugar-free liquid	Liquid, depending on product	Solid oral dosage form
Pediatric suitability	High, subject to taste and dosing volume	Variable	Lower for patients unable to swallow
Excipient differentiation	Flavor, sweetener, buffer, preservative	Usually limited	Tablet disintegrants, binders, coatings
Patent barrier	Limited apparent barrier	Limited apparent barrier	Limited apparent barrier
Main commercial risk	Taste, adherence, price	Price and substitution	Swallowability and dose flexibility
Manufacturing complexity	Liquid preservation and packaging	Similar	Solid-dose manufacturing
Biosimilar risk	None	None	None

CARNITOR SF can retain value where prescribers and patients prefer a known branded formulation, reliable supply, or a specific sugar-free presentation. Generic substitution and payer pressure remain the principal commercial threats.

What patent litigation and licensing deals affect CARNITOR SF?

No specific patent litigation, settlement agreement, or licensing transaction is established by the cited public sources for CARNITOR SF. The product’s commercial history is more consistent with an established, generic-exposed small-molecule product than with a current high-value patent dispute.

Any licensing strategy would likely focus on:

• Regional distribution rights.
• Pediatric metabolic-disease channels.
• Contract manufacturing.
• Flavor and delivery technology.
• Unit-dose packaging.
• Private-label supply.

A formulation license could have value if it covers a measurable performance advantage, such as reduced dose volume, improved taste, longer in-use stability, or a validated preservative-free multidose system. A generic sugar-free liquid alone is unlikely to create durable exclusivity without claims directed to a novel composition or delivery configuration.

What generic launch risks exist?

Generic entrants face several practical risks despite the absence of a strong apparent patent barrier:

• Poor taste relative to the branded product.
• Preservative failure after repeated opening.
• Inconsistent flavor or odor.
• Dosing-device errors.
• Higher manufacturing losses from liquid filling.
• Limited demand outside specialist metabolic medicine.
• Difficulty obtaining favorable payer placement.
• Patient switching resistance.

For the incumbent, the main defense is product quality and adherence performance. For a challenger, the opportunity is a lower-cost equivalent or a differentiated product with better sensory characteristics.

What is the revenue exposure and market outlook?

No public product-specific revenue figure is identified in the cited sources. Revenue exposure is likely concentrated in chronic-use patients with diagnosed carnitine deficiency, including pediatric and specialist metabolic populations.

Commercial value depends on:

• Number of treated patients.
• Daily dose and duration.
• Reimbursement status.
• Generic substitution rate.
• Regional availability.
• Specialist prescribing behavior.
• Product supply continuity.

A lifecycle product with improved taste, smaller dosing volume, and convenient packaging could command a premium in specialist channels. The opportunity is narrower than for mass-market chronic medicines, but patient persistence can support recurring demand.

Key Takeaways

• CARNITOR SF is a sugar-free levocarnitine oral solution whose value depends on usability and supply rather than active-ingredient patent exclusivity.
• The core excipient platform is an aqueous, buffered, flavored, saccharin-sweetened system preserved with methylparaben and propylparaben.
• Taste masking is the most commercially important formulation opportunity.
• A concentrated liquid, improved flavor, unit-dose package, or preservative-free presentation could support lifecycle differentiation.
• No controlling CARNITOR SF patent, Paragraph IV dispute, settlement, or licensing deal is established by the cited public sources.
• Biosimilar competition is irrelevant because levocarnitine is a small molecule.
• Generic risk is real, with competition likely to focus on price, approval pathway, sensory performance, and supply reliability.
• The strongest commercial opportunity is a patient-centric reformulation for pediatric and chronic-use populations.

FAQs

Is CARNITOR SF suitable for diabetic patients?

Its sugar-free positioning may be preferable to a sucrose-containing liquid, but the full inactive-ingredient profile and local labeling should control clinical and commercial claims.

Can CARNITOR SF be reformulated without parabens?

Yes, but a replacement would require product-specific preservative effectiveness, stability, microbial, packaging, and in-use studies. A preservative-free multidose product would require stronger packaging and in-use controls.

Is a concentrated levocarnitine liquid commercially attractive?

It can reduce dosing volume and shipping burden, but it may increase taste intensity, dosing risk, osmolality, and pediatric tolerability concerns.

Does CARNITOR SF have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Levocarnitine is a small-molecule drug and is subject to generic-drug pathways.

Can a new flavor create patent protection?

A flavor alone generally has limited exclusivity value. Stronger protection may require a novel composition, defined excipient ratios, improved stability, reduced dosing volume, or a validated delivery system with defensible patent claims.

References

1. U.S. Food and Drug Administration. (n.d.). Carnitor (levocarnitine) oral solution and tablets: Prescribing information. Leadiant Biosciences, Inc.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed.
4. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.
5. European Medicines Agency. (2017). Guideline on pharmaceutical development of medicines for paediatric use.